Key facts
- This page summarizes Peter Evan Harwin's Form 4 filing for Viridian Therapeutics, Inc.\DE (VRDN).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 28 Jun 2024, 16:05.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Award
Additional SEC filing notes
Footnote F1
The option vests in full upon the earlier to occur of (i) June 26, 2025 or (ii) the Issuer's 2025 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board.
Footnote F2
Under the Reporting Person's arrangement with Fairmount Funds Management LLC (the "Adviser"), the Reporting Person holds the option for one or more investment vehicles managed by the Adviser (each, a "Fairmount Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.
SEC remarks
Exhibit 24 - Power of Attorney